Browse 1 Avycaz Medical Studies Across 8 Cities
15 Avycaz Clinics
What Are Avycaz Clinical Trials?
Avycaz (Av-EE-Kaz) combines two different drugs: Ceftazidime and avibactam. Ceftazidime is an antibiotic and avibactam prevents antibiotics from being broken down by bacteria. This drug is given to people through intravenous (IV) infusion.
Avycaz treats complicated intra-abdominal infections (cIAI), urinary tract infections, and bacterial pneumonia. The FDA approved Avycaz on February 25, 2015. Avycaz is made by GlaxoSmithKline Manufacturing and distributed by Forest Pharmaceuticals, Inc.
Why Is Avycaz Being Studied In Clinical Trials?
Early studies showed that Avycaz is effective in treating cIAI infections., complicated urinary tract infections, and hospital-acquired and ventilator-associated bacterial pneumonia. This is supported by the previous findings that ceftazidime is also an effective treatment for cIAI. The efficacy of avibactam to Avycaz was initially studied in lab animals with infections. Later, studies were done with adults and children with intra-abdominal infections (cIAI), urinary tract infections, and bacterial pneumonia. The participants were chosen at random and did not know if they were getting the real drug or not (a double-blind study).
How Does Avycaz Treatment Work?
According to researchers, the ceftazidime component of Avycaz is an antibiotic that fights infections. It only works against some types of bacteria. Ceftazidime kills bacteria by binding to essential proteins that the bacteria need to survive. The avibactam component of Avycaz is a drug that decreases the activity of certain enzymes. This helps to slow down the breakdown of ceftazidime giving it more time to work. Avibactam makes ceftazidime last longer in the body so that it has more time to kill bacteria. Avycaz is effective against a variety of bacteria in both laboratory tests and infections in people.
What Are Some of the Breakthrough Clinical Trials Involving Avycaz?
A few of the most cited research findings on Avycaz are:
2013: Urinary Tract Infections - Multidrug-resistant bacteria are increasingly causing complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). Avycaz effectively treats deadly cUTI and cIAI infections that do not respond to other antibiotics.
2014: Antimicrobial resistance - Ceftolozane/tazobactam is an effective alternative to third-generation cephalosporins for people who have failed treatment or for people with infections from Gram-negative bacteria. The increased activity of ceftolozane/tazobactam against difficult-to-treat strains of Pseudomonas aeruginosa may lead to its use for the treatment of cUTI, cIAI, and VABPwith this bacterium.
2022: Bacterial Infections - Using antibiotics early and appropriately can lead to better clinical outcomes for people with serious infections. Studies have shown that using ceftazidime-avibactam can improve the outcomes of people with MDR Gram-negative infections. t
Who Are The Key Opinion Leaders On Avycaz Clinical Trial Research?
George G. Zhanel is a professor of the Department of Medical Microbiology at the University of Manitoba, Winnipeg, Canada. Professor Zhanel has published several studies in the fields of treatment and prevention of infectious diseases and pharmacokinetics.
Sankar Swaminathan, MD is an expert in treating infectious diseases and board certified in Internal Medicine and Infectious Diseases as well. His primary focus clinically is diagnosing and treating infections suffered by immunocompromised patients, such as cancer patients or organ transplant recipients. Additionally, he has integrated a research program funded by the National Cancer Institute exploring viruses' role in cancer into his clinical practice.